Altimmune (NASDAQ:ALT) Receives “Buy” Rating from HC Wainwright

Altimmune (NASDAQ:ALT)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $12.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 101.01% from the stock’s previous close.

A number of other research analysts have also recently commented on the company. Stifel Nicolaus initiated coverage on Altimmune in a report on Wednesday, January 8th. They issued a “buy” rating and a $18.00 price target on the stock. William Blair reiterated a “market perform” rating on shares of Altimmune in a research report on Friday. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $20.83.

Altimmune Price Performance

Shares of NASDAQ:ALT opened at $5.97 on Tuesday. The firm’s 50 day simple moving average is $6.45 and its two-hundred day simple moving average is $7.11. The company has a market capitalization of $459.77 million, a P/E ratio of -3.85 and a beta of 0.87. Altimmune has a 1-year low of $5.14 and a 1-year high of $11.16.

Altimmune (NASDAQ:ALT) last released its earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.00 million. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. On average, sell-side analysts anticipate that Altimmune will post -1.35 earnings per share for the current fiscal year.

Insider Activity at Altimmune

In related news, CFO Gregory L. Weaver purchased 10,000 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The stock was bought at an average price of $5.20 per share, for a total transaction of $52,000.00. Following the completion of the transaction, the chief financial officer now owns 10,000 shares in the company, valued at approximately $52,000. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. 4.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Altimmune

Several institutional investors have recently modified their holdings of ALT. Connor Clark & Lunn Investment Management Ltd. raised its holdings in Altimmune by 119.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 40,705 shares of the company’s stock valued at $250,000 after buying an additional 22,188 shares during the period. Intech Investment Management LLC bought a new position in Altimmune during the third quarter valued at $207,000. Charles Schwab Investment Management Inc. raised its stake in shares of Altimmune by 2.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock valued at $1,299,000 after acquiring an additional 4,772 shares during the period. Larson Financial Group LLC bought a new stake in shares of Altimmune in the 3rd quarter worth about $31,000. Finally, Summit Financial Wealth Advisors LLC boosted its stake in shares of Altimmune by 65.1% during the 3rd quarter. Summit Financial Wealth Advisors LLC now owns 45,918 shares of the company’s stock worth $282,000 after purchasing an additional 18,113 shares during the period. 78.05% of the stock is owned by institutional investors.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.